BGLC

BGLC is a $4.9M-market-cap Malaysian holding company (industrial-chemical distributor Chemrex plus early-stage genomic-screening arm MRNA Scientific) whose business is going backwards. Revenue has fallen every year from $13.4M in FY2021 to $7.42M in FY2025 (-21.9% YoY), driven by 'lower sales volume at Chemrex,' while the net loss widened to -$2.98M. Gross margin is a thin 14.6% and operating margin -39.9%, so the company loses roughly 40 cents on every revenue dollar — this is a distribution business, not a high-margin diagnostics story, and R&D of only $50.7K confirms the 'gene lab' branding is not where the money goes.

The balance sheet looks superficially clean — liabilities/equity of just 0.07x, $8.61M equity, $2.49M cash and positive working capital of $4.93M — but it is being steadily consumed. Operating cash flow was -$1.84M in FY2025 against $2.49M of cash, leaving little more than a year of runway, which is exactly why the MD&A leans on 'going concern and liquidity considerations' and states liquidity 'remains dependent on... access to capital.' The company already had to execute a 1-for-10 reverse split (effective April 2025) merely to cure a Nasdaq bid-price deficiency — a classic distressed micro-cap signal, and the reason the share count collapsed 86.5%.